Introduction
Assessment of clinical congestion has both therapeutic and prognostic implications for the management of patients with chronic heart failure (HF). In retrospective analyses of the Acute and Chronic Therapeutic Impact of a Vasopressin-2 Antagonist in Congestive Heart Failure (ACTIV in CHF) trial and in the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial, signs of congestion in patients with chronic HF were associated with both short-and long-term increased risk of all-cause death and HF hospitalization. 1, 2 Importantly, patients with asymptomatic LV dysfunction have a significantly increased risk of overt HF and mortality. Therefore, early detection of subclinical signs of impending haemodynamic derangement would be extremely useful to identify and treat these patients in order to prevent the progression of the disease.
Clinical congestion in HF constitutes the final common pathway for a host of cardiac disorders and is defined by the contemporary presence of high-left ventricular diastolic pressure associated with signs and symptoms of HF. Conversely, 'pulmonary congestion' defines a situation extravasation of fluids with an excess of extravascular lung water into the pulmonary interstitium, regardless of the presence or absence of signs and symptoms of HF. 3 Elevation of left ventricular filling pressure in HF patients without overt clinical congestion has been termed as 'haemodynamic congestion', and may precede both pulmonary and clinical congestion by days or even weeks. 4 Thus, clinical congestion may be considered as only the tip of the iceberg of the haemodynamic instability preceding symptoms. Bearing in mind that the primary goal for asymptomatic and mildly symptomatic HF would be to prevent or delay disease progression, haemodynamic goals are strongly supported in the modern era of advanced HF and outpatient HF management. 5 Currently, the gold standard for evaluating haemodynamic congestion in HF patients is cardiac catheterization to measure right atrial pressure and pulmonary capillary wedge pressure, 2, 6, 7 however it cannot be applied routinely in patients with congestive HF and in addition it lacks the ability to measure ventricular volumes. Echocardiography is the noninvasive method of choice for the evaluation of LV diastolic function, but may be sometimes misleading, with key indices yielding discrepant information, especially in acute HF, and the inclusion of many parameters in the guidelines perceived too complex and not practical to perform and repeat on every patient admitted with HF. 4, 8 Ultimately, no single non-invasive test can accurately detect and quantify haemodynamic congestion, and the ability to detect congestion by haemodynamic measurements remains a diagnostic challenge as it usually precedes clinical symptoms. A different approach to assess the presence of haemodynamic congestion is by measuring to what extent left ventricular dysfunction leads to an increase in pulmonary blood volume (PBV). In previous studies the PBV has been measured as the product of cardiac output and pulmonary transit time (PTT) by trans-pulmonary indicator dilution techniques, which are very invasive due to the need for double catheterization. In the last decade, cardiovascular magnetic resonance (CMR) has emerged as a new, non-invasive, yet highly accurate tool to quantify blood flow and changes in total heart volume by using direct volume measurements and PTT of intravenous contrast agents. In this study, we sought to explore the prognostic value of PBV determination by first-pass contrast-enhanced perfusion CMR in a population of chronic HF outpatients.
Methods

Study design and population
The PROVE-HF study was a prospective two-centre study carried out from January 2013 to January 2015, complying with the 1975 Declaration of Helsinki and approved by our Institutional Ethics Committee. All patients gave written informed consent and received standard optimal medical therapy according to the current guidelines. We screened all consecutive outpatients with left ventricular dysfunction and at least one previous episode of acute HF decompensation (ACC/AHA stage C), who were referred to our CMR laboratory for a contrast-enhanced scan. Exclusion criteria were as follows: (i) age <18 years; (ii) left ventricular ejection fraction >50%; (iii) New York Heart Association (NYHA) functional class III or IV symptoms; (iv) presence of any contra-indication to CMR and/or to administration of gadolinium-based contrast agents; (v) any hospitalization during the last month; and (vi) atrial fibrillation.
Of 118 eligible consecutive patients, 4 were excluded for low-quality images and 2 for claustrophobia. We finally enrolled 112 chronic stable HF outpatients (91 men, 67 ± 12 years) and 53 age-and sex-matched healthy controls.
All patients underwent a standard clinical assessment including medical history, physical examination, routine serum blood tests, and a same-day transthoracic echocardiogram and contrast-enhanced CMR.
Cardiovascular magnetic resonance
All patients were examined on 1.5-T scanners (CVi; GE Healthcare, Milwaukee, WI, USA and Achieva; Philips Medical System, Best, the Netherlands) using phased-array cardiac synergy coils for signal reception, a dedicated cardiac software and vectorcardiographic triggering. Biventricular function was assessed by breath-hold, steady-state, freeprecession cine imaging in cardiac short-axis, encompassing both ventricles by contiguous 8-mm thick slices (field of view 40 cm, repetition time/echo time = 2, flip angle 45 , matrix 224 Â 224, reconstruction matrix 256 Â 256, 30 cardiac phases, views per segment [12] [13] [14] [15] [16] [17] [18] [19] [20] . Pulmonary artery flow was evaluated using a breath-hold velocity encoded phase contrast gradient-echo cine sequence with the following parameters: TR/ TE 12/5 ms, flip angle 20 , field of view 30, phase field of view 1, matrix 192 Â 192, reconstruction matrix 256 Â 256, slice thickness 5 mm. Flow sensitivity was set to 150 cm/s of encoded velocity and corrected when aliasing occurred. Then, to correct phase offset errors, acquisition was repeated with the same slice orientation and parameters in a stationary phantom. CMR perfusion imaging was performed with the first pass technique as previously described 9. Briefly, a bolus of gadolinium-based contrast agent (0.05 mmol/kg at 4 mL/s of infusion velocity, Dotarem, Schering-AG, Berlin, Germany) was injected into a peripheral vein, followed by a saline flush (injection rate 4 mL/s). First pass images were obtained using cardiac-gated gradient echo-train echo planar pulse sequences. Images from three short axis planes (basal, middle, and apical) and from a horizontal long-axis view were acquired with the following parameters: field of view 30 mm, slice thickness 10 mm, no gap between each slice, repetition time 6 ms, echo time 1.1 ms, flip angle 20 , bandwidth 25 Hz, 60 phases, matrix 128 Â 128, reconstruction matrix 256 Â 256. Image acquisition was begun at the same time as the contrast media injection.
Image analysis
All CMR studies were analysed off-line using dedicated workstations and software (Advantage Workstation, GE Healthcare; MASS 6.1, Medis, Leiden, The Netherlands; MR WorkSpace 2.6.3.2, Philips Medical Systems Nederland B.V.) by two experienced operators (A.B. and G.T.) blinded to clinical and follow-up data.
Biventricular volumes and ejection fraction, as well as left ventricular mass, were determined using cine short-axis images. Left and right atrial areas were measured in the end-systolic frame of the four-chamber cine sequence, excluding atrial appendages and pulmonary veins. Pulmonary artery flow and aortic flow were measured by the analysis of velocity encoded phase contrast images using the conventional method. 9 The ef- 
Pulmonary transit time
A modified approach with respect to the method proposed by Ugander et al. 11 has been adopted to measure PTT. The heart is a pulsatile pump and with every heartbeat RV ejects in the pulmonary circulation an amount of blood equal to the anterograde RVSV. Hence, PTT may be measured as the number of cardiac cycles, or pulmonary transit beats (PTB), required for a bolus of contrast agent to pass from the RV to the left atrium. The gadolinium first-pass perfusion imaging allows us to obtain an image for each heartbeat for 60 consecutive beats and it may be used to measure the PTT. Briefly, in the horizontal long-axis view of first pass imaging, a region of interest was placed in the RV cavity and copied in the same position for the entire stack of images. The average signal intensity (SI) of the region of interest was measured in every images and a SI/heartbeat curve was generated ( Figure 1A and B). A second SI/heartbeat curve was generated from another region of interest placed in left atrium. The PTT was measured as the peak-to-peak time interval between the curves. PTB was defined by the peak-to-peak number of cardiac cycles between the two curves. In a preliminary study, we compared the measurement of PTT and PTB as onset-to-onset, peak-to-peak and half-width time interval of the wash-in phase of SI/heartbeat curves. In a preliminary evaluation, we found no significant differences among such methods, and we finally chose the peak-to-peak time interval as the most reproducible, yielding intra-class correlation coefficient values of 0.99 and 0.97 for intraobserver and inter-observer reliability, respectively.
Pulmonary blood volume
PBV was measured by the product of PTB and the anterograde RVSV, and indexed to body surface area as PBVI (mL/m 2 ) ( Figure 1A and B). This is better understood if one considers PBV as being analogous to a cargo train, with the number of wagons equivalent to the number of cardiac cycles for intravenous bolus of gadolinium contrast to pass through the pulmonary circulation, or PTB, being each individual wagon equal to the anterograde RVSV.
Transthoracic echocardiography
All patients underwent standard transthoracic echocardiography (TTE) immediately before the CMR examination. A comprehensive echocardiographic assessment of LV diastolic function was performed in agreement with international guidelines, 8 including structural assessment of LV size and mass, LA volume, mitral inflow and pulmonary venous flow patterns, pulsed-wave tissue-Doppler imaging of mitral annular velocities and systolic pulmonary artery pressure (sPAP). LV diastolic dysfunction was defined as the presence of a Grade II or III diastolic dysfunction with Doppler echocardiography.
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Clinical follow-up
Follow-up was performed until December 2016 by telephone interviews, reviews of clinical records, and contact with patients' primary care physician. Cause of death was classified according to modified Hinkle-Thaler system. Patients who died of noncardiac causes were censored at the time of the event. The predefined primary end point was a composite of cardiovascular death (HF, sudden death), hospitalization for HF (requiring intravenous diuretics and/or inotropes), and sustained symptomatic ventricular arrhythmias (requiring intravenous antiarrhythmic drugs and/or electrical cardioversion and/or appropriate defibrillator intervention). 
Statistical analysis
Results
Baseline characteristics of the study population are summarized in Tables 1 and 2 . All patients had a history of HF symptoms (ACC/AHA stage C) and were receiving optimal medical therapy. At enrolment, 60 patients (54%) were in NYHA functional class I, and 52 patients (46%) were in NYHA class II. Of 112 HF outpatients with LV dysfunction, 57 (51%) had been diagnosed with ischaemic cardiomyopathy, 37 (33%) with an idiopathic dilated cardiomyopathy (DCM), 5 patients (4%) with a genetic syndrome (1 Becker's muscular dystrophy and 4 laminopathies,), 8 patients (7%) had a previous myocarditis, 2 patients (2%) had incessant supraventricular tachycardia and developed tachycardiomyopathy, 3 patients (3%) had previous exposure to chemotherapy. Compared with controls, HF outpatients showed significantly increased LV volumes and mass, as well as reduced LV and RV ejection fraction. Both PTT and PBVI were significantly higher in patients compared to controls ( Table 1) .
Baseline characteristics of chronic HF outpatients stratified by PBVI values are reported in Table 2 . At a cut-off point for PBVI of 492 mL/m 2 (corresponding to 2 SD above the mean of our control population), 25 (22%) HF outpatients had increased PBVI. Compared with patients with normal PBVI, subjects with PBVI > 492 mL/m 2 were more likely to have more advanced diastolic dysfunction ( Figure 2 ) and worse biventricular systolic function (P < 0.001) ( Table 2) . Of note, PBVI was significantly associated with several echocardiographic indices of diastolic dysfunction by TTE (Figure 3) . In particular, PBVI showed a significant positive correlation with tissue-Doppler E/e' ratio and systolic pulmonary artery pressure by CW-Doppler ( Figure 3A and D) .
Survival analysis
During a median follow-up period of 26 ± 17 months, 16 patients (14%) underwent implantable cardioverter-defibrillator (ICD) implantation and 27 patients (24%) reached the primary composite end point: 4 cardiovascular death, 10 sustained ventricular arrhythmias (with or without appropriate ICD intervention), and 13 hospitalizations for acute decompensated HF. Of these, 18 patients showed abnormally high PBVI.
PBVI > 492 mL/m 2 was associated with a significant lower eventfree survival (log-rank test P < 0.001) (Figure 4) . On multivariableadjusted Cox regression analysis, PBVI was an independent predictor of the composite cardiovascular end point (P ¼ 0.03) ( Table 3) . Important interaction terms such as estimated glomerular filtration rate, left atrium area, right and left cardiac index, PTT, and LV mass were also included; however, none of the interactions were significant and therefore were not included in the final model of the analysis.
Discussion
In this proof-of-concept study, we have demonstrated the utility of first-pass perfusion imaging by CMR for the quantification of PBVI in HF outpatients. The major findings of this study were that: (i) HF outpatients showed higher PBVI and longer mean PTT compared with age-and sex-matched healthy controls; (ii) severity of diastolic dysfunction increased in parallel to the increase of PBVI; and (iii) PBVI was found to be an independent predictor of poor mid-term cardiovascular outcome.
The two main haemodynamic abnormalities leading to acute HF are low cardiac output and increased LV filling pressures, but the main reason by far for hospitalization for worsening HF is related to the symptoms of congestion. Importantly, many patients are discharged with persistent signs and symptoms of congestion, which has prognostic relevance in HF patients. Indeed, incomplete decongestion at discharge is a strong predictor of poor prognosis 13 and has been proposed as a major determinant of early death and HF readmission. Current HF guidelines recommend treating patients in order to improve symptoms and signs of congestion, and achieve near-optimal volume status prior to discharge. 14 Unfortunately, standardized metrics or (de)congestion scores are still an unmet clinical need. 4, 15 Currently, the gold standard for evaluating haemodynamic congestion in HF patients is cardiac catheterization to measure right atrial pressure, pulmonary artery wedge pressure and/or left ventricular end-diastolic pressure, but the invasive nature of catheterization limits its routine use in clinical practice. Multiple modalities have been introduced to estimate haemodynamic parameters without invasive measurement. Natriuretic peptides have been helpful in urgent care settings to suggest cardiac aetiology of dyspnoea and to identify patients at high or low risk for early adverse outcome, albeit related to wide inter-individual variability to ventricular filling pressures. 16, 17 Several non-invasive techniques, including external and internal bio-impedance measurement and Doppler echocardiography, have generated estimates significantly correlated with filling pressures and cardiac output. Unfortunately, these techniques lack accuracy to guide therapies on the basis of serial changes. 7 Furthermore, sensitivity and negative predictive value of the 2009 and 2016 echocardiographic grading algorithms for diagnosis of LV diastolic dysfunction have been recently questioned by the results of the multicentre EACVI Euro-Filling study. 18 Our knowledge of the haemodynamic of the pulmonary vascular bed is based on the measurement of three main variables: the pulmonary blood pressure, pulmonary blood flow, and PBV. Of these, PBV has found little clinical favour due to technical difficulties associated with its measurement that has largely limited its use so far. 19 Previous attempts have been based on invasive electromagnetic flowmetry or Stewart-Hamilton dye-dilution based techniques during both right heart and transseptal left heart catheterization, radioactive [20] [21] [22] [23] [24] [25] [26] However, catheterization is associated with potential major vascular complications, radionuclide studies pose the risk of radiation exposure, and echocardiography is of questionable accuracy for the quantification of cardiac output.
PTT is proportional to PBV, and represents the time for a bolus of contrast to pass from the right ventricle to the left ventricle, measured according to the indicator dilution principles. An increase in PTT reflects the reduction in cardiac output and an increase in PBV in HF. PTT by contrast-enhanced ultrasound has been shown to correlate to a fair degree with measures of systolic and diastolic function, NT-pro-BNP, pulmonary vascular status, right ventricular function and quality of life among patients with and without LV dysfunction, and has already been indicated as a biomarker of global cardiopulmonary function. 27, 28 Previous research has shown that variations in PBV and PTT can be accurately evaluated using CMR. Our study corroborates and extends preliminary findings supporting the feasibility of measuring PBVI by first-pass perfusion CMR imaging, 11, 32 and the ability of PBVI to differentiate between stages of diastolic dysfunction 28 and predict prognosis. 33 As a quantitative marker of HF, PBVI could be useful for early detection, grading and monitoring of haemodynamic congestion in patients with left ventricular dysfunction, especially during the so-called 'vulnerable phase'. This is a critical time-window during which nearly 30% of patients hospitalized with HF will be readmitted for HF or other cardiovascular reasons, due to the return or worsening of congestive symptoms with even a modest incremental rise in filling pressures after discharge. 31, 34 In this setting PBVI by CMR could be a sensitive tool to unravel poor haemodynamic reserve and help the clinician to tailor optimal medical treatment. As the list of indications to the use of CMR in HF patients is rapidly expanding, measurement of PTT and PBVI would certainly deserve appropriate consideration as a complementary clinical application. 35 Kanski et al. 36 observed that patients recently diagnosed with systemic sclerosis, as a group, have a reduced amount of PBVI, assessed by phase-contrast imaging and normalized to lung volume, compared to healthy controls. However, authors failed to observe a relationship between PBVI and sPAP, as estimated by Doppler echocardiography. The source of differences between that study and our results should be very carefully interpreted, taking into account how they might be affected by methodological issues and different patient populations.
Further studies are warranted in order to: (i) confirm our results; (ii) assess the utility of PBVI in different clinical settings; (iii) investigate the association between PBVI and serum levels of natriuretic peptides; (iv) determine whether PBVI has any incremental diagnostic and/or prognostic value above conventional diastolic function assessment; and (v) test the diagnostic accuracy of PBVI with established gold-standard invasive techniques for the measurement of pulmonary artery wedge pressure and LV filling pressure.
Limitations
We acknowledge that there are a few limitations of the present study. Firstly, because of the limited sample size and the relatively low event rate, the multivariable analysis is likely to be underpowered to derive a robust predictive model and our findings should only be intended as hypothesis generating. Secondly, the accuracy of measuring PBVI may be limited due to the uncertain relationship between the bolus concentration of contrast material and the SI on CMR images used for PTT measurements. Thirdly, the cut-off value of PBVI derived in our cohort of healthy controls is limited to the age group studied, thus larger cohorts are required to validate the sensitivity and specificity of PBVI at different cut-off points. Fourthly, we did not compare PBVI values to invasive haemodynamic measurements and serum levels of natriuretic peptides.
Lastly, CMR is a third level imaging technique and one might consider this application inappropriate because of the high cost. 
Conclusions
PBVI by contrast-enhanced CMR is a novel imaging application useful to quantitatively determine pulmonary intravascular blood pool and a promising surrogate marker of diastolic dysfunction. In our series of HF outpatients, increased PBVI was associated with an increase in the severity of diastolic dysfunction and poor cardiovascular outcome. Further studies are warranted to confirm our results and to assess the clinical and prognostic utility of PBVI by CMR in different clinical settings.
